Is United Therapeutics Corp. overvalued or undervalued?

As of 2 September 2025, the valuation grade for United Therapeutics Corp. has moved from very attractive to attractive, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 19, an EV to EBITDA of 13.67, and a PEG ratio of 0.93, which suggest that the stock is reasonably priced relative to its earnings growth potential.
In comparison to its peers, United Therapeutics Corp. has a higher P/E ratio than Incyte Corp. (22.95) but lower than Royalty Pharma Plc (12.26), indicating a competitive positioning within the industry. Additionally, the company's return performance has outpaced the S&P 500 across multiple periods, with a 1-month return of 30.49% compared to the S&P 500's 2.33%, reinforcing the attractiveness of the stock in the current market environment.